Endochin-like quinolones exhibit promising efficacy against neospora caninum in vitro and in experimentally infected pregnant mice

Nicoleta Anghel, Vreni Balmer, Joachim Müller, Pablo Winzer, Adriana Aguado-Martinez, Mona Roozbehani, Sovitj Pou, Aaron Nilsen, Michael Riscoe, Joseph Doggett, Andrew Hemphill

Research output: Contribution to journalArticle

Abstract

We report on the efficacy of selected endochin-like quinolones (ELQs) against N. caninum tachyzoites grown in human foreskin fibroblasts (HFF), and in a pregnant BALB/c mouse model. Fourteen ELQs were screened against transgenic N. caninum tachyzoites expressing β-galactosidase (Nc-βgal). Drugs were added concomitantly to infection and the values for 50% proliferation inhibition (IC50) were determined after 3 days. Three compounds exhibited IC50 values below 0.1 nM, 3 ELQs had IC50s between 0.1 and 1 nM, for 7 compounds values between 1 and 10 nM were noted, and one compound had an IC50 of 22.4 nM. Two compounds, namely ELQ-316 and its prodrug ELQ-334 with IC50s of 0.66 and 3.33 nM, respectively, were previously shown to display promising activities against experimental toxoplasmosis and babesiosis caused by Babesia microti in mice, and were thus further studied. They were assessed in long-term treatment assays by exposure of infected HFF to ELQs at 0.5 μM concentration, starting 3 h after infection and lasting for up to 17 days followed by release of drug pressure. Results showed that the compounds substantially delayed parasite proliferation, but did not exert parasiticidal activities. TEM of drug treated parasites detected distinct alterations within the parasite mitochondria, but not in other parasite organelles. Assessment of safety of ELQ-334 in the pregnant mouse model showed that the compound did not interfere in fertility or pregnancy outcome. In N. caninum infected pregnant mice treated with ELQ-334 at 10 mg/kg/day for 5 days, neonatal mortality (within 2 days post partum) was found in 7 of 44 pups (15.9%), but no postnatal mortality was noted, and vertical transmission was reduced by 49% compared to the placebo group, which exhibited 100% vertical transmission, neonatal mortality in 15 of 34 pups (44%), and postnatal mortality for 18 of the residual 19 pups during the 4 weeks follow-up. These findings encourage more research on the use of ELQs for therapeutic options against N. caninum infection.

Original languageEnglish (US)
Article number285
JournalFrontiers in Veterinary Science
Volume5
Issue numberNOV
DOIs
StatePublished - Nov 19 2018

Fingerprint

Neospora
quinolones
Neospora caninum
Quinolones
mice
Parasites
pups
Inhibitory Concentration 50
inhibitory concentration 50
neonatal mortality
Foreskin
parasites
tachyzoites
Infant Mortality
drugs
fibroblasts
Babesia microti
Fibroblasts
Infection
animal models

Keywords

  • Cytochromeb
  • Electron microscopy
  • Endochin-like quinolones
  • Mitochondrion
  • Mouse model
  • Neospora
  • Toxoplasma
  • Vertical transmission

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Endochin-like quinolones exhibit promising efficacy against neospora caninum in vitro and in experimentally infected pregnant mice. / Anghel, Nicoleta; Balmer, Vreni; Müller, Joachim; Winzer, Pablo; Aguado-Martinez, Adriana; Roozbehani, Mona; Pou, Sovitj; Nilsen, Aaron; Riscoe, Michael; Doggett, Joseph; Hemphill, Andrew.

In: Frontiers in Veterinary Science, Vol. 5, No. NOV, 285, 19.11.2018.

Research output: Contribution to journalArticle

Anghel, Nicoleta ; Balmer, Vreni ; Müller, Joachim ; Winzer, Pablo ; Aguado-Martinez, Adriana ; Roozbehani, Mona ; Pou, Sovitj ; Nilsen, Aaron ; Riscoe, Michael ; Doggett, Joseph ; Hemphill, Andrew. / Endochin-like quinolones exhibit promising efficacy against neospora caninum in vitro and in experimentally infected pregnant mice. In: Frontiers in Veterinary Science. 2018 ; Vol. 5, No. NOV.
@article{a2b419965e54462eaf415db9eff75cdf,
title = "Endochin-like quinolones exhibit promising efficacy against neospora caninum in vitro and in experimentally infected pregnant mice",
abstract = "We report on the efficacy of selected endochin-like quinolones (ELQs) against N. caninum tachyzoites grown in human foreskin fibroblasts (HFF), and in a pregnant BALB/c mouse model. Fourteen ELQs were screened against transgenic N. caninum tachyzoites expressing β-galactosidase (Nc-βgal). Drugs were added concomitantly to infection and the values for 50{\%} proliferation inhibition (IC50) were determined after 3 days. Three compounds exhibited IC50 values below 0.1 nM, 3 ELQs had IC50s between 0.1 and 1 nM, for 7 compounds values between 1 and 10 nM were noted, and one compound had an IC50 of 22.4 nM. Two compounds, namely ELQ-316 and its prodrug ELQ-334 with IC50s of 0.66 and 3.33 nM, respectively, were previously shown to display promising activities against experimental toxoplasmosis and babesiosis caused by Babesia microti in mice, and were thus further studied. They were assessed in long-term treatment assays by exposure of infected HFF to ELQs at 0.5 μM concentration, starting 3 h after infection and lasting for up to 17 days followed by release of drug pressure. Results showed that the compounds substantially delayed parasite proliferation, but did not exert parasiticidal activities. TEM of drug treated parasites detected distinct alterations within the parasite mitochondria, but not in other parasite organelles. Assessment of safety of ELQ-334 in the pregnant mouse model showed that the compound did not interfere in fertility or pregnancy outcome. In N. caninum infected pregnant mice treated with ELQ-334 at 10 mg/kg/day for 5 days, neonatal mortality (within 2 days post partum) was found in 7 of 44 pups (15.9{\%}), but no postnatal mortality was noted, and vertical transmission was reduced by 49{\%} compared to the placebo group, which exhibited 100{\%} vertical transmission, neonatal mortality in 15 of 34 pups (44{\%}), and postnatal mortality for 18 of the residual 19 pups during the 4 weeks follow-up. These findings encourage more research on the use of ELQs for therapeutic options against N. caninum infection.",
keywords = "Cytochromeb, Electron microscopy, Endochin-like quinolones, Mitochondrion, Mouse model, Neospora, Toxoplasma, Vertical transmission",
author = "Nicoleta Anghel and Vreni Balmer and Joachim M{\"u}ller and Pablo Winzer and Adriana Aguado-Martinez and Mona Roozbehani and Sovitj Pou and Aaron Nilsen and Michael Riscoe and Joseph Doggett and Andrew Hemphill",
year = "2018",
month = "11",
day = "19",
doi = "10.3389/fvets.2018.00285",
language = "English (US)",
volume = "5",
journal = "Frontiers in Veterinary Science",
issn = "2297-1769",
publisher = "Frontiers Media S. A.",
number = "NOV",

}

TY - JOUR

T1 - Endochin-like quinolones exhibit promising efficacy against neospora caninum in vitro and in experimentally infected pregnant mice

AU - Anghel, Nicoleta

AU - Balmer, Vreni

AU - Müller, Joachim

AU - Winzer, Pablo

AU - Aguado-Martinez, Adriana

AU - Roozbehani, Mona

AU - Pou, Sovitj

AU - Nilsen, Aaron

AU - Riscoe, Michael

AU - Doggett, Joseph

AU - Hemphill, Andrew

PY - 2018/11/19

Y1 - 2018/11/19

N2 - We report on the efficacy of selected endochin-like quinolones (ELQs) against N. caninum tachyzoites grown in human foreskin fibroblasts (HFF), and in a pregnant BALB/c mouse model. Fourteen ELQs were screened against transgenic N. caninum tachyzoites expressing β-galactosidase (Nc-βgal). Drugs were added concomitantly to infection and the values for 50% proliferation inhibition (IC50) were determined after 3 days. Three compounds exhibited IC50 values below 0.1 nM, 3 ELQs had IC50s between 0.1 and 1 nM, for 7 compounds values between 1 and 10 nM were noted, and one compound had an IC50 of 22.4 nM. Two compounds, namely ELQ-316 and its prodrug ELQ-334 with IC50s of 0.66 and 3.33 nM, respectively, were previously shown to display promising activities against experimental toxoplasmosis and babesiosis caused by Babesia microti in mice, and were thus further studied. They were assessed in long-term treatment assays by exposure of infected HFF to ELQs at 0.5 μM concentration, starting 3 h after infection and lasting for up to 17 days followed by release of drug pressure. Results showed that the compounds substantially delayed parasite proliferation, but did not exert parasiticidal activities. TEM of drug treated parasites detected distinct alterations within the parasite mitochondria, but not in other parasite organelles. Assessment of safety of ELQ-334 in the pregnant mouse model showed that the compound did not interfere in fertility or pregnancy outcome. In N. caninum infected pregnant mice treated with ELQ-334 at 10 mg/kg/day for 5 days, neonatal mortality (within 2 days post partum) was found in 7 of 44 pups (15.9%), but no postnatal mortality was noted, and vertical transmission was reduced by 49% compared to the placebo group, which exhibited 100% vertical transmission, neonatal mortality in 15 of 34 pups (44%), and postnatal mortality for 18 of the residual 19 pups during the 4 weeks follow-up. These findings encourage more research on the use of ELQs for therapeutic options against N. caninum infection.

AB - We report on the efficacy of selected endochin-like quinolones (ELQs) against N. caninum tachyzoites grown in human foreskin fibroblasts (HFF), and in a pregnant BALB/c mouse model. Fourteen ELQs were screened against transgenic N. caninum tachyzoites expressing β-galactosidase (Nc-βgal). Drugs were added concomitantly to infection and the values for 50% proliferation inhibition (IC50) were determined after 3 days. Three compounds exhibited IC50 values below 0.1 nM, 3 ELQs had IC50s between 0.1 and 1 nM, for 7 compounds values between 1 and 10 nM were noted, and one compound had an IC50 of 22.4 nM. Two compounds, namely ELQ-316 and its prodrug ELQ-334 with IC50s of 0.66 and 3.33 nM, respectively, were previously shown to display promising activities against experimental toxoplasmosis and babesiosis caused by Babesia microti in mice, and were thus further studied. They were assessed in long-term treatment assays by exposure of infected HFF to ELQs at 0.5 μM concentration, starting 3 h after infection and lasting for up to 17 days followed by release of drug pressure. Results showed that the compounds substantially delayed parasite proliferation, but did not exert parasiticidal activities. TEM of drug treated parasites detected distinct alterations within the parasite mitochondria, but not in other parasite organelles. Assessment of safety of ELQ-334 in the pregnant mouse model showed that the compound did not interfere in fertility or pregnancy outcome. In N. caninum infected pregnant mice treated with ELQ-334 at 10 mg/kg/day for 5 days, neonatal mortality (within 2 days post partum) was found in 7 of 44 pups (15.9%), but no postnatal mortality was noted, and vertical transmission was reduced by 49% compared to the placebo group, which exhibited 100% vertical transmission, neonatal mortality in 15 of 34 pups (44%), and postnatal mortality for 18 of the residual 19 pups during the 4 weeks follow-up. These findings encourage more research on the use of ELQs for therapeutic options against N. caninum infection.

KW - Cytochromeb

KW - Electron microscopy

KW - Endochin-like quinolones

KW - Mitochondrion

KW - Mouse model

KW - Neospora

KW - Toxoplasma

KW - Vertical transmission

UR - http://www.scopus.com/inward/record.url?scp=85057045794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057045794&partnerID=8YFLogxK

U2 - 10.3389/fvets.2018.00285

DO - 10.3389/fvets.2018.00285

M3 - Article

VL - 5

JO - Frontiers in Veterinary Science

JF - Frontiers in Veterinary Science

SN - 2297-1769

IS - NOV

M1 - 285

ER -